Kymera Therapeutics, Inc. (KYMR) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $86.71 (+1.31%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 26, 2026 | Judah Frommer | Morgan Stanley | $123.00 | +41.9% |
| Feb 26, 2026 | Brian Abrahams | RBC Capital | $108.00 | +24.6% |
| Jan 27, 2026 | Eliana Merle | Barclays | $133.00 | +53.4% |
| Dec 11, 2025 | Sudan Loganathan | Stephens | $110.00 | +26.9% |
| Dec 9, 2025 | Srikripa Devarakonda | Truist Financial | $116.00 | +33.8% |
| Dec 9, 2025 | Andrew Fein | H.C. Wainwright | $134.00 | +54.5% |
| Dec 9, 2025 | Derek Archila | Wells Fargo | $116.00 | +33.8% |
| Dec 8, 2025 | Jeet Mukherjee | BTIG | $138.00 | +59.2% |
| Dec 8, 2025 | Alex Thompson | Stifel Nicolaus | $114.00 | +31.5% |
| Nov 4, 2025 | Jeff Jones | Oppenheimer | $67.00 | -22.7% |
| Nov 3, 2025 | Brad Canino | Guggenheim | $90.00 | +3.8% |
| Oct 22, 2025 | Jeet Mukherjee | BTIG | $75.00 | -13.5% |
| Sep 16, 2025 | Brian Abrahams | RBC Capital | $70.00 | -19.3% |
| Jun 27, 2025 | Jeff Jones | Oppenheimer | $53.00 | -38.9% |
| Jun 26, 2025 | Jeet Mukherjee | BTIG | $59.00 | -32.0% |
| Jun 25, 2025 | Kelly Shi | Jefferies | $64.00 | -26.2% |
| Jun 3, 2025 | Michael Schmidt | Guggenheim | $60.00 | -30.8% |
| Dec 5, 2024 | Etzer Darout | BMO Capital | $55.00 | -36.6% |
| Dec 2, 2024 | Derek Archila | Wells Fargo | $57.00 | -34.3% |
| Sep 27, 2024 | Jeff Jones | Oppenheimer | $56.00 | -35.4% |
Top Analysts Covering KYMR
KYMR vs Sector & Market
| Metric | KYMR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.10 | 2.24 | 2.40 |
| Analyst Count | 10 | 8 | 19 |
| Target Upside | +30.8% | +11475.0% | +17.1% |
| P/E Ratio | -22.72 | 3.93 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $2M | $8M | $18M | 12 |
| 2026-09-30 | $3M | $10M | $22M | 10 |
| 2026-12-31 | $3M | $11M | $23M | 11 |
| 2027-03-31 | $3M | $10M | $23M | 6 |
| 2027-06-30 | $4M | $15M | $33M | 6 |
| 2027-09-30 | $4M | $15M | $33M | 6 |
| 2027-12-31 | $4M | $15M | $33M | 6 |
| 2028-12-31 | $4M | $43M | $104M | 17 |
| 2029-12-31 | $4M | $54M | $130M | 14 |
| 2030-12-31 | $18M | $222M | $535M | 8 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-1.07 | $-0.93 | $-0.73 | 13 |
| 2026-09-30 | $-2.45 | $-0.95 | $-0.04 | 5 |
| 2026-12-31 | $-2.48 | $-0.96 | $-0.04 | 5 |
| 2027-03-31 | $-2.67 | $-1.03 | $-0.04 | 5 |
| 2027-06-30 | $-2.57 | $-0.99 | $-0.04 | 5 |
| 2027-09-30 | $-2.59 | $-1.00 | $-0.04 | 5 |
| 2027-12-31 | $-2.62 | $-1.01 | $-0.04 | 5 |
| 2028-12-31 | $-5.31 | $-4.34 | $-3.07 | 14 |
| 2029-12-31 | $-12.42 | $-4.39 | $0.85 | 8 |
| 2030-12-31 | $-9.41 | $-3.32 | $0.65 | 12 |
Frequently Asked Questions
What is the analyst consensus for KYMR?
The consensus among 10 analysts covering Kymera Therapeutics, Inc. (KYMR) is Buy with an average price target of $117.31.
What is the highest price target for KYMR?
The highest price target for KYMR is $138.00, set by Jeet Mukherjee at BTIG on 2025-12-08.
What is the lowest price target for KYMR?
The lowest price target for KYMR is $32.00, set by Richard Law at Credit Suisse on 2022-12-06.
How many analysts cover KYMR?
10 analysts have issued ratings for Kymera Therapeutics, Inc. in the past 12 months.
Is KYMR a buy or sell right now?
Based on 10 analyst ratings, KYMR has a consensus rating of Buy (2.10/5) with a +30.8% upside to the consensus target of $117.31.
What are the earnings estimates for KYMR?
Analysts estimate KYMR will report EPS of $-0.93 for the period ending 2026-06-30, with revenue estimated at $8M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.